Ferroptosis’s Master Switch GPX4 emerges as universal biomarker for precision immunotherapy: a pan-cancer study with in vitro experiments validation
Collectively, these pan-cancer analyses underscore the potential of GPX4 as a therapeutic target and biomarker in multiple cancers. Further indepth studies on GPX4's regulatory mechanisms and clinicopathological significance are warranted to develop novel therapies for the prevention and treatment of human tumors.
Authors
- Ruihua Dong (ORCID: https://orcid.org/0000-0003-3463-5023)
- Min Zhu (ORCID: https://orcid.org/0000-0002-7468-0083)
- Xiao Li (ORCID: https://orcid.org/0000-0001-7866-3160)
Institutions
- National Clinical Research Center for Digestive Diseases (CN)
- Beijing Friendship Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-09
- DOI
- https://doi.org/10.3389/fonc.2025.1643235
- Citations
- 1
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.52